ReviewEwha medical journal2024
Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review.
Review in Ewha medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The association between liver fat content and plasma metabolite profiles in fasting and postprandial states: an integration of a cohort study and a randomized controlled trial.Cardiovascular diabetology · 2026Trial
- Trial
- Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.Journal of global health · 2026Article
- Odds for Presence of Metabolic Dysfunction Associated Steatotic Liver Disease ( MASLD) in Individuals with Reported Hepatic Steatosis on Ultrasound.Pakistan journal of medical sciences · 2026Article
- Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules · 2026Review
- Hepatocyte Models for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Non-HepG2 Cell Models.International journal of molecular sciences · 2026Review
- Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study.Diabetes, obesity & metabolism · 2026Article
- Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia.BMC gastroenterology · 2026Article
- Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- Sex and gender disparities in hepatocellular carcinoma: insights into risk, diagnosis, and therapeutic outcomes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Review
- KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025.Clinical and molecular hepatology · 2025Article
- The Prevalence of Liver Enzyme Abnormalities Among Adult Patients with Non-Communicable Diseases in Rwanda: A Gender-Stratified Analysis.Hepatic medicine : evidence and research · 2025Article
- Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Short-Term Progression of Carotid Atherosclerosis Among Early Middle Age Adults.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the effects of sex and sex differences on liver health and disease is crucial for individualized healthcare and informed decision-making for patients with liver disease. The impact of sex on liver disease varies according to its etiology. Women have a lower prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) than men. However, postmenopausal women face a higher risk of advanced liver fibrosis due to hormonal influences. Sex differences affect the pathogenesis of MASLD, which involves a complex process involving several factors such as hormones, obesity, and the gut microbiome. Furthermore, sex-related differences in the development of MASLDrelated hepatocellular carcinoma have been observed. The sex-specific characteristics of MASLD necessitate an individualized management approach based on scientific evidence. However, research in this area has been lacking. This article reviews the current understanding of sex differences in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.